Section of Neonatology, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
Division of Pulmonology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
Semin Perinatol. 2023 Oct;47(6):151817. doi: 10.1016/j.semperi.2023.151817. Epub 2023 Sep 9.
Bronchopulmonary dysplasia (BPD) is the leading cause of chronic lung disease in infants and the commonest complication of prematurity. Advances in respiratory and overall neonatal care have increased the survival of extremely low gestational age newborns, leading to the continued high incidence of BPD. Pulmonary hypertension (PH) represents the severe form of the pulmonary vascular disease associated with BPD, and affects almost one-third of infants with moderate to severe BPD. PH responds suboptimally to pulmonary vasodilators and increases morbidity and mortality in BPD infants. An up-to-date knowledge of the pathogenesis, pathophysiology, diagnosis, treatment, and outcomes of BPD-PH can be helpful to develop meaningful and novel strategies to improve the outcomes of infants with this disorder. Therefore, our multidisciplinary team has attempted to thoroughly review and summarize the latest advances in BPD-PH in preventing and managing this morbid lung disorder of preterm infants.
支气管肺发育不良(BPD)是婴儿慢性肺部疾病的主要原因,也是早产儿最常见的并发症。呼吸和整体新生儿护理的进步提高了极低胎龄新生儿的存活率,导致 BPD 的发病率持续居高不下。肺动脉高压(PH)是与 BPD 相关的严重肺血管疾病,影响了近三分之一患有中重度 BPD 的婴儿。PH 对肺血管扩张剂反应不佳,增加了 BPD 婴儿的发病率和死亡率。对 BPD-PH 的发病机制、病理生理学、诊断、治疗和结局的最新了解有助于制定有意义和新颖的策略,以改善患有这种疾病的婴儿的结局。因此,我们的多学科团队试图全面审查和总结 BPD-PH 在预防和管理早产儿这种肺部疾病方面的最新进展。